Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Ryan Fukushima sold 23,818 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $46.19, for a total transaction of $1,100,153.42. Following the completion of the transaction, the chief executive officer directly owned 143,945 shares in the company, valued at approximately $6,648,819.55. The trade was a 14.20% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total value of $1,910,168.76.
- On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.
- On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total value of $597,148.50.
Tempus AI Stock Up 12.9%
TEM stock opened at $52.05 on Friday. The firm has a market capitalization of $9.35 billion, a PE ratio of -36.15 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The stock’s 50 day moving average is $51.33 and its 200-day moving average is $51.95.
Analysts Set New Price Targets
TEM has been the topic of a number of recent analyst reports. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. BTIG Research decreased their price objective on shares of Tempus AI from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, Freedom Capital raised Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Tempus AI currently has an average rating of “Hold” and a consensus price target of $64.92.
Check Out Our Latest Research Report on TEM
Hedge Funds Weigh In On Tempus AI
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc lifted its position in shares of Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after buying an additional 102,878 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after acquiring an additional 36,096 shares during the period. Bogart Wealth LLC raised its stake in Tempus AI by 365,087.5% in the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares during the period. Eagle Health Investments LP purchased a new stake in Tempus AI during the first quarter valued at about $11,588,000. Finally, Alethea Capital Management LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $1,863,000. 24.22% of the stock is owned by hedge funds and other institutional investors.
Tempus AI Company Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
- Five stocks we like better than Tempus AI
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
